Chemotherapy for advanced pancreatic cancer
- 1 July 2003
- journal article
- review article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 56 (4), 16-23
- https://doi.org/10.1016/s0360-3016(03)00448-6
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297Journal of Clinical Oncology, 2002
- A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancerBritish Journal of Cancer, 2002
- Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinomaCancer, 2002
- Marimastat as First-Line Therapy for Patients With Unresectable Pancreatic Cancer: A Randomized TrialJournal of Clinical Oncology, 2001
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerAnnals of Oncology, 1996
- Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreasInvestigational New Drugs, 1994
- Pancreatic CarcinomaNew England Journal of Medicine, 1992
- A phase III trial on the therapy of advanced pancreatic carcinoma evaluations of the mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatinCancer, 1990
- Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.BMJ, 1980